PURPOSE: To assess the efficacy and safety of using simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) to treat nasopharyngeal cancer (NPC) in a Caucasian cohort. Outcome was analyzed with respect to dose-volume histogram (DVH) values. PATIENTS AND METHODS: Between 03/2002 and 01/2008, 39 NPC patients underwent SIB-IMRT (37 Caucasians; 31 males; mean age 53 years [16-78 years]). 41% presented with WHO (World Health Organization) type 1 unfavorable histology, 85% with stage III/IV disease. 19 patients had total gross tumor volume (GTV) 16-70 cm3 (mean 36 cm3), while 16 had GTV > 70 cm3 (73-217 cm3; mean 115 cm3). All patients with stage II-IV disease received concomitant cisplatin. The prescribed SIB dose delivered to the planning target volume (PTV) was 70 Gy (2.00 Gy/fraction) in 17, 69.6 Gy (2.11 Gy/fraction) in 19, and 66 Gy (2.20 Gy/fraction) in three patients. RESULTS: 3-year local relapse-free, nodal relapse-free, distant metastases-free, disease-free rates and overall survival were 86%, 89%, 85%, 72%, and 85% (median follow-up 30 months [8-71 months]). Histology was a significant prognostic factor concerning overall survival, with worst prognosis in WHO type 1 compared to type 2/3 (75% vs. 93%; p = 0.03). There was a trend in favor of WHO type 2/3 regarding local control (74% vs. 94%; p = 0.052). The PTV DVHs showed a slight left shift compared to reported series. Three patients developed grade 3 late effects (xerostomia [n = 2], dysphagia [n = 1], hearing loss [n = 1]). CONCLUSION: In comparison with predominantly Asian NPC IMRT series in the literature, chemo-IMRT in the own Caucasian cohort, characterized by less radio-responsive WHO type 1, was equally effective. Treatment tolerance was excellent.
PURPOSE: To assess the efficacy and safety of using simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) to treat nasopharyngeal cancer (NPC) in a Caucasian cohort. Outcome was analyzed with respect to dose-volume histogram (DVH) values. PATIENTS AND METHODS: Between 03/2002 and 01/2008, 39 NPCpatients underwent SIB-IMRT (37 Caucasians; 31 males; mean age 53 years [16-78 years]). 41% presented with WHO (World Health Organization) type 1 unfavorable histology, 85% with stage III/IV disease. 19 patients had total gross tumor volume (GTV) 16-70 cm3 (mean 36 cm3), while 16 had GTV > 70 cm3 (73-217 cm3; mean 115 cm3). All patients with stage II-IV disease received concomitant cisplatin. The prescribed SIB dose delivered to the planning target volume (PTV) was 70 Gy (2.00 Gy/fraction) in 17, 69.6 Gy (2.11 Gy/fraction) in 19, and 66 Gy (2.20 Gy/fraction) in three patients. RESULTS: 3-year local relapse-free, nodal relapse-free, distant metastases-free, disease-free rates and overall survival were 86%, 89%, 85%, 72%, and 85% (median follow-up 30 months [8-71 months]). Histology was a significant prognostic factor concerning overall survival, with worst prognosis in WHO type 1 compared to type 2/3 (75% vs. 93%; p = 0.03). There was a trend in favor of WHO type 2/3 regarding local control (74% vs. 94%; p = 0.052). The PTV DVHs showed a slight left shift compared to reported series. Three patients developed grade 3 late effects (xerostomia [n = 2], dysphagia [n = 1], hearing loss [n = 1]). CONCLUSION: In comparison with predominantly Asian NPC IMRT series in the literature, chemo-IMRT in the own Caucasian cohort, characterized by less radio-responsive WHO type 1, was equally effective. Treatment tolerance was excellent.
Authors: M A Hunt; M J Zelefsky; S Wolden; C S Chui; T LoSasso; K Rosenzweig; L Chong; S V Spirou; L Fromme; M Lumley; H A Amols; C C Ling; S A Leibel Journal: Int J Radiat Oncol Biol Phys Date: 2001-03-01 Impact factor: 7.038
Authors: S L Wolden; P G Steinherz; D H Kraus; M J Zelefsky; D G Pfister; N Wollner Journal: Int J Radiat Oncol Biol Phys Date: 2000-03-01 Impact factor: 7.038
Authors: Dora L W Kwong; Jonathan S T Sham; Lucullus H T Leung; Ashley C K Cheng; W M Ng; Philip W K Kwong; W M Lui; C C Yau; P M Wu; William Wei; Gordon Au Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-05 Impact factor: 7.038
Authors: G Sanguineti; F B Geara; A S Garden; S L Tucker; K K Ang; W H Morrison; L J Peters Journal: Int J Radiat Oncol Biol Phys Date: 1997-03-15 Impact factor: 7.038
Authors: Suzanne L Wolden; William C Chen; David G Pfister; Dennis H Kraus; Sean L Berry; Michael J Zelefsky Journal: Int J Radiat Oncol Biol Phys Date: 2005-06-02 Impact factor: 7.038
Authors: A Zabel-du Bois; S Nill; S Ulrich; U Oelfke; B Rhein; P Haering; S Milker-Zabel; A Schwahofer Journal: Strahlenther Onkol Date: 2012-01-05 Impact factor: 3.621
Authors: M Picchio; M Kirienko; P Mapelli; I Dell'Oca; E Villa; F Gallivanone; L Gianolli; C Messa; I Castiglioni Journal: Eur J Nucl Med Mol Imaging Date: 2013-08-29 Impact factor: 9.236
Authors: Stefan Janssen; Christoph Glanzmann; Bita Yousefi; Karl Loewenich; Gerhard Huber; Stephan Schmid; Gabriela Studer Journal: Mol Clin Oncol Date: 2015-05-04
Authors: Edwin Bölke; Gisela Schieren; Stephan Gripp; Gerald Steinbach; Matthias Peiper; Klaus Orth; Christiane Matuschek; Maximilian Pelzer; Guido Lammering; Ruud Houben; Christina Antke; Lars Christian Rump; Rodrigo Mota; Peter Arne Gerber; Patrick Schuler; Thomas K Hoffmann; Ethelyn Rusnak; Derik Hermsen; Wilfried Budach Journal: Strahlenther Onkol Date: 2011-02-24 Impact factor: 3.621